[go: up one dir, main page]

ITMI20041763A1 - Nuove formulazioni iniettabili contenenti progesterone - Google Patents

Nuove formulazioni iniettabili contenenti progesterone

Info

Publication number
ITMI20041763A1
ITMI20041763A1 IT001763A ITMI20041763A ITMI20041763A1 IT MI20041763 A1 ITMI20041763 A1 IT MI20041763A1 IT 001763 A IT001763 A IT 001763A IT MI20041763 A ITMI20041763 A IT MI20041763A IT MI20041763 A1 ITMI20041763 A1 IT MI20041763A1
Authority
IT
Italy
Prior art keywords
formulations containing
injectable formulations
containing progesterone
new injectable
new
Prior art date
Application number
IT001763A
Other languages
English (en)
Inventor
Marco Pizzutti
Nadia Puppini
Giorgio Zoppetti
Original Assignee
Altergon Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IT001763A priority Critical patent/ITMI20041763A1/it
Application filed by Altergon Sa filed Critical Altergon Sa
Publication of ITMI20041763A1 publication Critical patent/ITMI20041763A1/it
Priority to CN200510109646.4A priority patent/CN1748705B/zh
Priority to CN201510127629.7A priority patent/CN104857522A/zh
Priority to CA2519418A priority patent/CA2519418C/en
Priority to JP2005266457A priority patent/JP5102949B2/ja
Priority to ES05108494.5T priority patent/ES2460730T3/es
Priority to PT51084945T priority patent/PT1637167E/pt
Priority to DK05108494.5T priority patent/DK1637167T3/da
Priority to PL05108494T priority patent/PL1637167T3/pl
Priority to EP05108494.5A priority patent/EP1637167B1/en
Priority to US11/229,212 priority patent/US20060058262A1/en
Priority to HK06109833.6A priority patent/HK1089372B/en
Priority to US12/964,321 priority patent/US20110082127A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT001763A 2004-09-15 2004-09-16 Nuove formulazioni iniettabili contenenti progesterone ITMI20041763A1 (it)

Priority Applications (13)

Application Number Priority Date Filing Date Title
IT001763A ITMI20041763A1 (it) 2004-09-16 2004-09-16 Nuove formulazioni iniettabili contenenti progesterone
CN200510109646.4A CN1748705B (zh) 2004-09-16 2005-09-14 包含孕酮的新的可注射制剂
CN201510127629.7A CN104857522A (zh) 2004-09-16 2005-09-14 包含孕酮的新的可注射制剂
CA2519418A CA2519418C (en) 2004-09-15 2005-09-14 New injectable formulations containing progesterone
JP2005266457A JP5102949B2 (ja) 2004-09-16 2005-09-14 プロゲステロンを有する新規の注入可能製剤
ES05108494.5T ES2460730T3 (es) 2004-09-16 2005-09-15 Formulaciones inyectables que contienen un complejo entre progesterona e hidroxipropil-betaciclodextrina
EP05108494.5A EP1637167B1 (en) 2004-09-16 2005-09-15 Injectable formulations containing a complex between progesterone and hydroxypropyl-beta-cyclodextrin
PT51084945T PT1637167E (pt) 2004-09-16 2005-09-15 Formulações injetáveis que contêm um complexo entre progesterona e hidroxipropil-beta-ciclodextrina
DK05108494.5T DK1637167T3 (da) 2004-09-16 2005-09-15 Injicerbare formuleringer indeholdende et kompleks mellem progesteron og hydroxypropyl-beta-cyclodextrin
PL05108494T PL1637167T3 (pl) 2004-09-16 2005-09-15 Preparaty do injekcji zawierające kompleks progesteronu i hydroksypropylo-beta-cyklodekstryny
US11/229,212 US20060058262A1 (en) 2004-09-16 2005-09-16 New injectable formulations containing progesterone
HK06109833.6A HK1089372B (en) 2004-09-16 2006-09-05 Injectable formulations containing a complex between progesterone and hydroxypropyl-beta-cyclodextrin
US12/964,321 US20110082127A1 (en) 2004-09-16 2010-12-09 New injectable formulations containing progesterone

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT001763A ITMI20041763A1 (it) 2004-09-16 2004-09-16 Nuove formulazioni iniettabili contenenti progesterone

Publications (1)

Publication Number Publication Date
ITMI20041763A1 true ITMI20041763A1 (it) 2004-12-16

Family

ID=35463649

Family Applications (1)

Application Number Title Priority Date Filing Date
IT001763A ITMI20041763A1 (it) 2004-09-15 2004-09-16 Nuove formulazioni iniettabili contenenti progesterone

Country Status (10)

Country Link
US (2) US20060058262A1 (it)
EP (1) EP1637167B1 (it)
JP (1) JP5102949B2 (it)
CN (2) CN1748705B (it)
CA (1) CA2519418C (it)
DK (1) DK1637167T3 (it)
ES (1) ES2460730T3 (it)
IT (1) ITMI20041763A1 (it)
PL (1) PL1637167T3 (it)
PT (1) PT1637167E (it)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9107696B2 (en) * 2008-08-06 2015-08-18 Emory University Method of embryo transfer that eliminates transferred air while hormonally inducing implantation and apparatus
CA2789238C (en) * 2010-03-09 2020-05-12 Dignity Health Methods for inhibiting preterm labor and uterine contractility disorders and preventing cervical ripening
US9271991B2 (en) 2010-10-27 2016-03-01 Dignity Health Trimegestone (TMG) for treatment of preterm birth
US8586527B2 (en) 2011-10-20 2013-11-19 Jaipal Singh Cerivastatin to treat pulmonary disorders
RU2019104004A (ru) 2012-01-23 2019-03-07 Сейдж Терапьютикс, Инк. Лекарственные формы нейроактивных стероидов и способы лечения нарушений цнс
LT2887944T (lt) 2012-08-21 2022-01-10 Sage Therapeutics, Inc. Alopregnanolonas, skirtas atsparios epileptinės būklės gydymui
ITMI20122027A1 (it) * 2012-11-28 2014-05-29 Altergon Sa Soluzioni acquose orali di ormoni steroidei e hp¿cd con biodisponibilità ottimizzata
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
MA45276A (fr) 2015-06-18 2018-04-25 Sage Therapeutics Inc Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation
CN106727288A (zh) * 2016-11-10 2017-05-31 南京斯泰尔医药科技有限公司 水溶性黄体酮注射液组合物及制备方法
CN107950649A (zh) * 2017-11-30 2018-04-24 浙江农林大学 一种抗冷害的果蔬保鲜涂膜剂及其制备方法和应用
CN109381424A (zh) * 2018-11-21 2019-02-26 南京泽恒医药技术开发有限公司 稳定的黄体酮水溶注射剂及其制备方法
CN113520990A (zh) * 2021-07-01 2021-10-22 浙江仙琚制药股份有限公司 一种黄体酮温敏凝胶注射液及其制备方法
CN116459212B (zh) * 2023-04-27 2024-01-30 石家庄四药有限公司 一种水溶性黄体酮注射液及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5527558A (en) * 1978-08-18 1980-02-27 Tokico Ltd Gas spring
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US6962944B2 (en) * 2001-07-31 2005-11-08 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
CN1517091A (zh) * 2003-01-16 2004-08-04 董英杰 黄体酮制剂及制备方法

Also Published As

Publication number Publication date
JP5102949B2 (ja) 2012-12-19
DK1637167T3 (da) 2014-05-19
ES2460730T3 (es) 2014-05-14
EP1637167B1 (en) 2014-02-12
EP1637167A3 (en) 2006-04-05
EP1637167A2 (en) 2006-03-22
CN1748705A (zh) 2006-03-22
CN1748705B (zh) 2015-04-22
CA2519418C (en) 2013-06-11
JP2006083171A (ja) 2006-03-30
HK1089372A1 (en) 2006-12-01
US20060058262A1 (en) 2006-03-16
PL1637167T3 (pl) 2014-09-30
CA2519418A1 (en) 2006-03-16
CN104857522A (zh) 2015-08-26
PT1637167E (pt) 2014-05-26
US20110082127A1 (en) 2011-04-07

Similar Documents

Publication Publication Date Title
EP1788047A4 (en) WATER REPELLENT / OIL-REPELLING COMPOSITION
DK1812025T3 (da) Stabiliserede bakteriofagformuleringer
BRPI0511900A (pt) composições farmacêuticas
ITMI20041252A1 (it) Composizioni perfluoroelastomeriche
EP1749857A4 (en) Curable composition
CY2014030I1 (el) Θεραπευτικες συνθεσεις που περιλαμβανουν ingenol-3-angelate
ATE515548T1 (de) Stabilisierte iodkohlenstoffzusammensetzungen
EP1795261A4 (en) hONEYCOMB STRUCTURE
ITMI20041571A1 (it) Perfluoroelastomeri
EP1719409A4 (en) INSECTICIDE COMPOSITION
DK1776090T3 (da) Stabiliseret prostaglandinsammensætning
DE602005008726D1 (de) Verwendet
ES2845143T8 (es) Composición de trombina estable
DE602005027222D1 (de) Schaumbare zusammensetzung
DE602005016978D1 (de) Quecksilberfreisetzende Zusammensetzungen
DK1612200T3 (da) Gødningssammensætning
ITMI20041763A1 (it) Nuove formulazioni iniettabili contenenti progesterone
EP1787623A4 (en) Dental polymerizable composition
DE502005007117D1 (de) Dosierpumpe
DE602005017191D1 (de) Geruchsreduzierte waschstück-zusammensetzung
DE602005013911D1 (de) Gefüllte perfluorpolymere
FR2875801B1 (fr) Coulis de ciment-mousse
ITTO20040012A1 (it) Tintometro
FR2871686B1 (fr) Composition anti-decoloration
ITMI20041447A1 (it) Composizione farmaceutica comprendente gabapentina